These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
59 related articles for article (PubMed ID: 16729460)
1. [Xolair is approved in the USA and the EU]. Kärnell A Lakartidningen; 2006 May 3-9; 103(18):1450; author reply 1450-1. PubMed ID: 16729460 [No Abstract] [Full Text] [Related]
2. Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations. Tsuji K; Tsutani K Eur J Pharm Biopharm; 2008 Mar; 68(3):496-502. PubMed ID: 17884403 [TBL] [Abstract][Full Text] [Related]
7. Lost in translation: differences in antimicrobial indication approval policies between the United States and Europe. Pappas G; Ierodiakonou V; Falagas ME Clin Ther; 2009 Jul; 31(7):1595-603. PubMed ID: 19695409 [TBL] [Abstract][Full Text] [Related]
8. EU law mandates drug testing in children. Sinha G J Natl Cancer Inst; 2008 Jan; 100(2):84-5. PubMed ID: 18182609 [No Abstract] [Full Text] [Related]
9. Biopharmaceuticals approved in the EU 1995-1999: a European Union-United States comparison. Reichert JM; Healy EM Eur J Pharm Biopharm; 2001 Jan; 51(1):1-7. PubMed ID: 11154897 [TBL] [Abstract][Full Text] [Related]
10. Researchers see a need for speed in EU trial approvals. Cressey D Nat Med; 2008 Aug; 14(8):794. PubMed ID: 18685580 [No Abstract] [Full Text] [Related]
11. Remicade approved for children with Crohn's disease. FDA Consum; 2006; 40(4):6. PubMed ID: 17245830 [No Abstract] [Full Text] [Related]
12. [Investigation on new molecular entities of drugs approved in three regions, Japan, U.S. and EU--common and preceding approvals in current 4 years]. Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2006; (124):80-2. PubMed ID: 17405529 [TBL] [Abstract][Full Text] [Related]
13. Changes in regulations for approval of therapeutics. Reichert JM MAbs; 2010; 2(4):359-60. PubMed ID: 25225706 [TBL] [Abstract][Full Text] [Related]
16. Treatment for wet macular degeneration. FDA Consum; 2006; 40(5):6. PubMed ID: 17326303 [No Abstract] [Full Text] [Related]
17. How European regulators view foreign data in the approval process. Breckenridge A; Hudson I Clin Pharmacol Ther; 2008 Sep; 84(3):311-2. PubMed ID: 18714321 [TBL] [Abstract][Full Text] [Related]
18. New adjuvants: EU regulatory developments. Sesardic D; Rijpkema S; Patel BP Expert Rev Vaccines; 2007 Oct; 6(5):849-61. PubMed ID: 17931163 [TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies: production, uses and side effects. Cowden J; Parker SK Pediatr Infect Dis J; 2006 Jun; 25(6):553-5. PubMed ID: 16732156 [No Abstract] [Full Text] [Related]
20. MS drug back on market under restricted program. FDA Consum; 2006; 40(4):7. PubMed ID: 17243280 [No Abstract] [Full Text] [Related] [Next] [New Search]